Fagron NV (FAGR) - Net Assets

Latest as of December 2025: €556.26 Million EUR ≈ $650.32 Million USD

Based on the latest financial reports, Fagron NV (FAGR) has net assets worth €556.26 Million EUR (≈ $650.32 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.24 Billion ≈ $1.45 Billion USD) and total liabilities (€686.87 Million ≈ $803.03 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FAGR asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets €556.26 Million
% of Total Assets 44.75%
Annual Growth Rate 8.39%
5-Year Change 70.91%
10-Year Change 263.87%
Growth Volatility 40.12

Fagron NV - Net Assets Trend (2004–2025)

This chart illustrates how Fagron NV's net assets have evolved over time, based on quarterly financial data. Also explore Fagron NV asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Fagron NV (2004–2025)

The table below shows the annual net assets of Fagron NV from 2004 to 2025. For live valuation and market cap data, see FAGR company net worth.

Year Net Assets Change
2025-12-31 €556.26 Million
≈ $650.32 Million
+10.07%
2024-12-31 €505.36 Million
≈ $590.82 Million
+8.07%
2023-12-31 €467.63 Million
≈ $546.70 Million
+14.44%
2022-12-31 €408.63 Million
≈ $477.73 Million
+25.55%
2021-12-31 €325.47 Million
≈ $380.50 Million
+26.24%
2020-12-31 €257.82 Million
≈ $301.42 Million
+4.62%
2019-12-31 €246.44 Million
≈ $288.12 Million
+17.51%
2018-12-31 €209.72 Million
≈ $245.18 Million
+13.43%
2017-12-31 €184.88 Million
≈ $216.15 Million
+20.94%
2016-12-31 €152.87 Million
≈ $178.73 Million
+336.01%
2015-12-31 €-64.77 Million
≈ $-75.73 Million
-141.27%
2014-12-31 €156.94 Million
≈ $183.48 Million
+1.14%
2013-12-31 €155.17 Million
≈ $181.41 Million
-36.77%
2012-12-31 €245.38 Million
≈ $286.88 Million
+11.31%
2011-12-31 €220.45 Million
≈ $257.73 Million
+5.92%
2010-12-31 €208.12 Million
≈ $243.32 Million
+5.99%
2009-12-31 €196.35 Million
≈ $229.56 Million
+5.83%
2008-12-31 €185.53 Million
≈ $216.90 Million
+4.10%
2007-12-31 €178.22 Million
≈ $208.36 Million
+87.84%
2006-12-31 €94.88 Million
≈ $110.93 Million
+14.50%
2005-12-31 €82.87 Million
≈ $96.88 Million
-19.19%
2004-12-31 €102.54 Million
≈ $119.88 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Fagron NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 2807500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock €532.87 Million 96.60%
Other Comprehensive Income €-11.00K 0.00%
Other Components €46.82 Million 8.49%
Total Equity €551.61 Million 100.00%

Fagron NV Competitors by Market Cap

The table below lists competitors of Fagron NV ranked by their market capitalization.

Company Market Cap
China Security & Fire Co Ltd Class A
SHG:600654
$1.65 Billion
Collective Mining Ltd
TO:CNL
$1.65 Billion
Celltrion Pharm Inc
KQ:068760
$1.65 Billion
Mister Car Wash, Inc. Common Stock
NYSE:MCW
$1.65 Billion
Jiangsu Jiangyin Rural Commercial Bank Co Ltd
SHE:002807
$1.65 Billion
Airport City Ltd
TA:ARPT
$1.65 Billion
Hotel Shilla
KO:008770
$1.65 Billion
KTK Group Co Ltd
SHG:603680
$1.65 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Fagron NV's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 501,386,000 to 551,609,000, a change of 50,223,000 (10.0%).
  • Net income of 91,020,000 contributed positively to equity growth.
  • Dividend payments of 26,002,000 reduced retained earnings.
  • Share repurchases of 4,136,000 reduced equity.
  • New share issuances of 8,342,000 increased equity.
  • Other comprehensive income increased equity by 264,066,999.
  • Other factors decreased equity by 283,067,999.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €91.02 Million +16.5%
Dividends Paid €26.00 Million -4.71%
Share Repurchases €4.14 Million -0.75%
Share Issuances €8.34 Million +1.51%
Other Comprehensive Income €264.07 Million +47.87%
Other Changes €-283.07 Million -51.32%
Total Change €- 10.02%

Book Value vs Market Value Analysis

This analysis compares Fagron NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.19x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 6.32x to 3.19x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2004-12-31 €3.80 €24.00 x
2005-12-31 €3.07 €24.00 x
2006-12-31 €3.51 €24.00 x
2007-12-31 €6.22 €24.00 x
2008-12-31 €5.48 €24.00 x
2009-12-31 €5.95 €24.00 x
2010-12-31 €6.33 €24.00 x
2011-12-31 €6.59 €24.00 x
2012-12-31 €7.20 €24.00 x
2013-12-31 €4.51 €24.00 x
2014-12-31 €4.60 €24.00 x
2015-12-31 €-2.00 €24.00 x
2016-12-31 €2.78 €24.00 x
2017-12-31 €2.52 €24.00 x
2018-12-31 €2.86 €24.00 x
2019-12-31 €3.32 €24.00 x
2020-12-31 €3.50 €24.00 x
2021-12-31 €4.40 €24.00 x
2022-12-31 €5.52 €24.00 x
2023-12-31 €6.35 €24.00 x
2024-12-31 €6.87 €24.00 x
2025-12-31 €7.51 €24.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Fagron NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 16.50%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.56%
  • • Asset Turnover: 0.77x
  • • Equity Multiplier: 2.25x
  • Recent ROE (16.50%) is above the historical average (12.12%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2004 13.46% 4.87% 1.04x 2.66x €3.54 Million
2005 18.18% 5.32% 1.04x 3.28x €6.78 Million
2006 12.78% 4.38% 0.97x 3.01x €2.63 Million
2007 9.12% 5.34% 0.88x 1.95x €-1.56 Million
2008 8.21% 4.20% 0.85x 2.30x €-3.26 Million
2009 10.11% 5.02% 0.83x 2.43x €208.40K
2010 10.92% 5.30% 0.74x 2.79x €1.90 Million
2011 12.99% 5.72% 0.72x 3.14x €6.47 Million
2012 18.17% 8.03% 0.73x 3.10x €19.74 Million
2013 -21.18% -8.31% 0.48x 5.31x €-47.26 Million
2014 10.49% 3.63% 0.46x 6.30x €763.40K
2015 0.00% -42.78% 0.69x 0.00x €-195.58 Million
2016 -13.73% -4.87% 0.49x 5.80x €-35.54 Million
2017 25.72% 10.68% 0.74x 3.27x €28.52 Million
2018 20.64% 9.01% 0.69x 3.32x €21.90 Million
2019 23.01% 10.41% 0.67x 3.31x €31.48 Million
2020 23.55% 10.72% 0.74x 2.97x €34.29 Million
2021 19.06% 10.63% 0.72x 2.50x €28.99 Million
2022 17.29% 10.18% 0.70x 2.41x €29.35 Million
2023 15.21% 9.25% 0.76x 2.17x €24.17 Million
2024 16.07% 9.24% 0.80x 2.16x €30.42 Million
2025 16.50% 9.56% 0.77x 2.25x €35.86 Million

Industry Comparison

This section compares Fagron NV's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

No peer company data available for comparison.

About Fagron NV

BR:FAGR Belgium Drug Manufacturers - Specialty & Generic
Market Cap
$2.06 Billion
€1.76 Billion EUR
Market Cap Rank
#6987 Global
#36 in Belgium
Share Price
€24.00
Change (1 day)
+0.00%
52-Week Range
€19.58 - €24.40
All Time High
€24.40
About

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more